|
Next generation sequencing of primary prostate cancer tumors to reveal potentially actionable opportunities for clinical management: The UNC experience. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Strata Oncology |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis (I) |
Research Funding - Bayer; Cerulean Pharma; Genentech/Roche; Lilly; Merck; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Merck (I) |
Expert Testimony - Wockhardt Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb; GeneCentric; Roche/Genentech; X4 Pharma |
|
|
Honoraria - Cardinal Health |
Consulting or Advisory Role - Noona Healthcare; SIVAN Innovation |
Other Relationship - American Society of Clinical Oncology; Centers for Medicare and Medicaid Services; Exelixis; JAMA-Journal of the American Medical Association; National Cancer Institute |
|
|
Consulting or Advisory Role - BioClin Therapeutics |
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
Research Funding - Astellas Pharma (Inst); Clovis Oncology (Inst); Innocrin Pharma (Inst); Inovio Pharmaceuticals (Inst) |